Anti-CS1 antibodies and antibody drug conjugates
AssigneeAbbVie Biotherapeutics Inc.
InventorsKurt C. Gish, Han K. Kim, Louie Naumovski
Life of this patent
Estimating the term…
Abstract
The present disclosure provides antibodies and antibody drug conjugates that bind human CS1 and their uses to treat subjects diagnosed with a plasma cell neoplasm, for example, multiple myeloma.
Claims20
An antibody drug conjugate (“ADC”) comprising a cytotoxic and/or cytostatic agent linked to an antibody by way of a linker, wherein the antibody comprises six CDRs in which:
- VH CDR#1 has an amino acid sequence DYYMA (SEQ ID NO:100),
- VH CDR#2 has an amino acid sequence SINYDGSSTYYVDSVKG (SEQ ID NO:104),
- VH CDR#3 has an amino acid sequence DRGYYFDY (SEQ ID NO:111),
- VL CDR#1 has an amino acid sequence RSSQSLVHSNGNTYLH (SEQ ID NO:114),
- VL CDR#2 has an amino acid sequence KVSNRFS (SEQ ID NO:121), and
- VL CDR#3 has an amino acid sequence SQSTHVPPFT (SEQ ID NO:123).
An antibody drug conjugate (“ADC”) comprising a cytotoxic and/or cytostatic agent linked to an antibody by way of a linker, wherein the ADC has a structure according to formula (I):
- [D-L-XY-]n-Ab (I)
- or a salt thereof, wherein:
- D is the antineoplastic drug;
- L is the linker;
- Ab is the antibody;
- XY represents a covalent linkage linking linker L to antibody Ab;
- and
- n is an integer ranging from 2 to 8;
- and wherein Ab comprises six CDRs in which:
- VH CDR#1 has an amino acid sequence DYYMA (SEQ ID NO:100),
- VH CDR#2 has an amino acid sequence SINYDGSSTYYVDSVKG (SEQ ID NO:104),
- VH CDR#3 has an amino acid sequence DRGYYFDY (SEQ ID NO:111),
- VL CDR#1 has an amino acid sequence RSSQSLVHSNGNTYLH (SEQ ID NO:114),
- VL CDR#2 has an amino acid sequence KVSNRFS (SEQ ID NO:121), and
- VL CDR#3 has an amino acid sequence SQSTHVPPFT (SEQ ID NO:123).
A composition comprising an antibody-drug conjugate (“ADC”) and a carrier, excipient or diluent,
- wherein the ADC comprises a cytotoxic and/or cytostatic agent linked to an antibody by way of a linker, the antibody comprising six CDRs in which:
- VH CDR#1 has an amino acid sequence DYYMA (SEQ ID NO:100),
- VH CDR#2 has an amino acid sequence SINYDGSSTYYVDSVKG (SEQ ID NO:104),
- VH CDR#3 has an amino acid sequence DRGYYFDY (SEQ ID NO:111),
- VL CDR#1 has an amino acid sequence RSSQSLVHSNGNTYLH (SEQ ID NO:114),
- VL CDR#2 has an amino acid sequence KVSNRFS (SEQ ID NO:121), and
- VL CDR#3 has an amino acid sequence SQSTHVPPFT (SEQ ID NO:123).
Dependencies are inferred from the claim text.